Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease.

MLA

Fathallah-Shaykh, Sahar, et al. “Efficacy and Safety of Sevelamer Carbonate in Hyperphosphatemic Pediatric Patients with Chronic Kidney Disease.” Pediatric Nephrology, vol. 33, no. 2, Feb. 2018, pp. 325–33. EBSCOhost, https://doi.org/10.1007/s00467-017-3787-0.

APA

Fathallah-Shaykh, S., Drozdz, D., Flynn, J., Jenkins, R., Wesseling-Perry, K., Swartz, S. J., Wong, C., Accomando, B., Cox, G. F., & Warady, B. A. (2018). Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease. Pediatric Nephrology, 33(2), 325–333. https://doi.org/10.1007/s00467-017-3787-0

Chicago

Fathallah-Shaykh, Sahar, Dorota Drozdz, Joseph Flynn, Randall Jenkins, Katherine Wesseling-Perry, Sarah J. Swartz, Craig Wong, Beverly Accomando, Gerald F. Cox, and Bradley A. Warady. 2018. “Efficacy and Safety of Sevelamer Carbonate in Hyperphosphatemic Pediatric Patients with Chronic Kidney Disease.” Pediatric Nephrology 33 (2): 325–33. doi:10.1007/s00467-017-3787-0.